SNRNP25 and osteosarcoma: In our in vitro cell experiments, we found that LRP1–SNRNP25 promotes the invasion and migration of osteosarcoma cells through the pJNK/37LRP/MMP2 signaling pathway, which can be inhibited by treatment with the pJNK inhibitor SP600125 or the MMP2 inhibitor marimastat.